Neura.net: Perspectives on CNS Disease Management
Member Login  |  Site Map  |  Disclaimer  |  Contact  |  Bookmark
Advanced Search
Text Size
 |  Monday, September 06, 2010 
Home
 
 
Home > Nurse Network > MS Scan > Issue 25 (2010)
Issue 25 (2010)
Download MS Scan Issue 25 (2010)
 

Featured in this issue of MS Scan is a summary of recently published results from trials of MS therapeutics, specifically, those that are taken orally. The latest clinical trial results of the oral MS therapies cladribine and fingolimod are discussed, along with a round-up of research data on several other oral therapies under investigation. A review of the mind-body connection in MS addresses the roles of depression, gender, and cognitive impairment in the MS disease course.


    A New Year’s Look at the MS Horizon    PDF
Over the last few months, research in MS therapeutics has been buzzing with the results of a number of clinical trials of oral MS therapies. The results of a placebo-controlled trial of cladribine and 2 trials of fingolimod present data on the efficacy of each drug. Ongoing research with 3 other oral MS therapies— laquinimod, teriflunomide, and dimethyl fumarate—is also covered in this article. Since approval of the first oral MS therapy seems likely within the next year, a special section addresses some of the questions patients may ask concerning oral MS therapy.
 
   New Findings on the Mind-Body Connection in MS    PDF
At every stage of disease, MS interacts profoundly with mental health, cognitive functioning, and quality of life (QoL). The interplay of mind and body in MS influences overall wellness, the ability to cope with illness, and adherence to therapy. Several recent studies have illuminated various aspects of mental health and cognition and their impact on MS, ranging from mental QoL and disability to prognosis for disease progression. Topics addressed include gender and pain, depression, and cognitive impairment.


   
Neura.net is administered, managed, and populated by Expert Medical Education, a company dedicated to the education of healthcare professionals. The individual educational materials available here are supported by educational grants from Teva Neuroscience. This site is intended for U.S. audiences only. This Web site is for use by healthcare professionals only. It is not meant to serve as a substitute for a consultation with your physician. If you are a patient and would like to see Neura.net's educational material for patients, click here. Some discussions of drugs and devices contained on this Web site may include mention of uses that have not been evaluated by the United States Food and Drug Administration for safety and efficacy. Please consult complete prescribing information for any of the drugs and devices discussed before using them.
© 2010 Neura.net. All rights reserved.